Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.55 |
| ▸ | S1PR5 | Q9H228 | 6/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PRKX | P51817 | 1/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1975861 | 1.00 | RORC (0.55) | RORCS1PR5S1PR1SIGMAR1HTR2A | |
| SCHEMBL2782848 | 1.00 | RORC (0.55) | RORCS1PR5S1PR1SIGMAR1HTR2A | |
| SCHEMBL4162044 | 1.00 | RORC (0.55) | RORCS1PR5S1PR1SIGMAR1HTR2A | |
| SCHEMBL1344798 | 0.90 | RORC (0.53) | RORCS1PR5S1PR1SIGMAR1HTR2A | |
| SCHEMBL1975601 | 0.90 | RORC (0.53) | RORCS1PR5S1PR1SIGMAR1HTR2A | |
| SCHEMBL2229912 | 0.90 | RORC (0.53) | RORCS1PR5S1PR1SIGMAR1HTR2A | |
| SCHEMBL1345133 | 0.90 | RORC (0.53) | RORCS1PR5S1PR1SIGMAR1HTR2A | |
| SCHEMBL3337004 | 0.89 | RORC (0.52) | RORCS1PR5S1PR1F10PRKX | |
| SCHEMBL1993817 | 0.89 | RORC (0.52) | RORCS1PR5S1PR1F10PRKX | |
| SCHEMBL16780160 | 0.89 | RORC (0.52) | RORCS1PR5S1PR1F10PRKX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-RE48334-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-01 | — | — | US | disclosed |
| US-9096520-B2 | Tricyclic ideno-pyrrole derivatives as serotonin receptor modulators | ABT HOLDING COMPANY (US) | 2015-08-04 | — | — | US | disclosed |
| EP-2336105-B9 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL (JP) | 2014-09-17 | — | — | EP | disclosed |
| US-20140206739-A1 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | ABT HOLDING COMPANY (US) | 2014-07-24 | — | — | US | disclosed |
| US-8716324-B2 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | ATHERSYS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2336105-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-8592454-B2 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-26 | — | — | US | disclosed |
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| EP-2513052-A1 | PYRROLIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| WO-2010069793-A1 | PROCESS FOR THE PREPARATION OF PYROLLIDINE-3-CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010059922-A1 | PYRROLIDINE CARBOXAMIDE COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-05-27 | — | — | WO | disclosed |
| EP-2185540-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| US-20090239925-A1 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| WO-2009019163-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | WO | disclosed |
| US-20090042896-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | US | disclosed |
| EP-1841738-A2 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | Athersys, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| WO-2007081299-A2 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS, INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| US-20060025601-A1 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | ATHERSYS, INC. | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025601-A1 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | HTR5A, HTR3E, HTR1E | RORC 527/4885S1PR5 455/4885S1PR1 997/4885 |
| US-20090239925-A1 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | HTR5A, HTR3E, HTR1E | RORC 527/4885S1PR5 455/4885S1PR1 997/4885 |
| US-20090042896-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | OPRL1, OPRK1, OPRD1 | RORC 517/4885S1PR5 1603/4885S1PR1 1154/4885 |
| US-20140206739-A1 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | HTR5A, HTR3E, HTR1E | RORC 527/4885S1PR5 455/4885S1PR1 997/4885 |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | RORC 2859/4885S1PR5 493/4885S1PR1 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.